

SUPPORTING INFORMATION

Maria Torres-Werlé,^[a] Adela Nano,^[a] Aline Maise-François,^[a] Stéphane Bellemin-
Laponnaz*^[a,b]

^[a] Dr. M. Torres-Werlé, A. Nano, Dr. A. Maise-François, Dr. S. Bellemin-Laponnaz,
Institut de Physique et Chimie des Matériaux de Strasbourg, Université de Strasbourg,
CNRS UMR 7504, 23 rue du Loess, BP 43, F-67034 Strasbourg Cedex 2, France
Fax: (+33) 388 107 246
E-mail: bellemin@unistra.fr


^[b] Dr. S. Bellemin-Laponnaz
Institute for Advanced Study, Université de Strasbourg, France.

General considerations

All manipulations (except catalytic runs) were performed under an inert atmosphere of argon or nitrogen using standard Schlenk line techniques. Valinol and phenylglycinol were obtained by reduction of Valine and Phenylglycine, respectively.^[1] All other reagents were commercially available and used as received. Solvents were purified and degassed by standard procedures. Metal complexes were obtained using methanol as solvent (ACS reagent grade). ¹H and ¹³C Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker AVANCE 300 spectrometer using the residual solvent peak as reference (CDCl₃: δ_H = 7.26 ppm; δ_C = 77.16 ppm) at 298K. Chemical shifts are given in ppm (δ) compared to TMS (tetramethylsilane). Infrared (IR) spectra were recorded on a Nicolet 380 FT-IR spectrometer. KBr discs were made for all samples. Elemental analyses were recorded by the 'Institut de Chimie' laboratory, Université de Strasbourg. HRMS ESI analyses were recorded on microTOF, Bruker Daltonics by the 'Institut de Chimie' laboratory, Université de Strasbourg. Specific rotations were recorded at the 'Laboratoire de Stéréochimie', ECPM, Strasbourg. HPLC analyses were performed on a Gilson apparatus (UV-VIS156/321 PUMP) with Chiralcel Daicel columns (AD, OD-H, AS, 0.46 X 25 cm) using *n*-Hexane/*i*-PrOH eluents. A dual wavelength UV detector was used. To confirm the retention times of both enantiomers, all racemic derivatives were prepared and injected on chiral HPLC. *i*Pr-DiBox (1), Ph-DiBox (2), *i*Pr-TriBox (3) and *i*Pr-TetraBox (4) have been prepared as previously reported.^[2]

Methods Used to Assay Enantiomeric Excess

Conversions and ee determinations of the nitroaldolisation product


| Product | ee assay | Conditions | Retention time of enantiomer 1 (min) | Retention time of enantiomer 2 (min) | [α] Solvent |
|---|-------------------------------|---|--------------------------------------|--------------------------------------|--|
|  | HPLC Chiralcel OD-H column | Hexane/ <i>i</i> PrOH 90/10 flow: 0.9 mL/min | 21.5 | 25.0 (major enantiomer) | (-) CH ₂ Cl ₂ |

For other ee assays, see :

a) D. A. Evans, D. Seidel, M. Rueping, H. W. Lam, J. T. Shaw, C. W. Downey, *J. Am. Chem. Soc.* **2003**, *125*, 12692.

- b) Y. Xiong, F. Wang, X. Huang, Y. Wen, X. Feng, *Chem. Eur. J.* **2007**, *13*, 829.
- c) M. Bandini, F. Piccinelli, S. Tommasi, A. Umami-Ronchi, C. Ventrici, *Chem. Commun.* **2007**, 616.
- d) I. Panov, P. Drabina, Z. Padelkova, P. Simunek, M. Sedlák, *J. Org. Chem.* **2011**, *76*, 4787.
- e) G. Lai, F. Guo, Y. Zheng, Y. Fang, H. Song, K. Xu, S. Wang, Z. Zha, Z. Wang, *Chem. Eur. J.* **2011**, *17*, 1114.



Conversions and ee determinations of the benzylation product

| Product | ee assay | Conditions | Retention time of enantiomer 1 (min) | Retention time of enantiomer 2 (min) | [α] Solvent |
|--|-------------------------------|---|--------------------------------------|--------------------------------------|--|
|  1(R),2(S) | HPLC Chiracel AD column | Hexane/ <i>i</i> PrOH 80/20 flow: 1 mL/min | 11.2 | 19.0 (major enantiomer) | (+) CH ₂ Cl ₂ |

For other ee assays, see :

- a) Y. Matsumura, T. Maki, S. Murakami, O. Onomura, *J. Am. Chem. Soc.* **2003**, *125*, 2052
- b) D. Nakamura, K. Kakiuchi, K. Koga, R. Shirai, *Org. Lett.* **2006**, *8*, 6139.
- c) E. P. Kündig, A. E. Garcia, T. Lomberget, P. Perez Garcia, P. Romanens, *Chem. Commun.* **2008**, 3519

Conversions and ee determinations of the benzylation product and diol

| Product | ee assay | Conditions | Retention time of enantiomer 1 (min) | Retention time of enantiomer 2 (min) | [α] Solvent |
|--|-------------------------------|---|--------------------------------------|--------------------------------------|--------------------------|
|  (1R,2R) | HPLC Chiracel AS column | Hexane/ <i>i</i> PrOH 85/15 flow: 0.9 mL/min | 11.1 | 14.5 | (+) CHCl ₃ |
|  (S,S) | HPLC Chiracel AS column | Hexane/ <i>i</i> PrOH 85/15 flow: 0.9 mL/min | 9.6 | 12.5 | (+) CHCl ₃ |


For other ee assays, see :

- a) Y. Matsumura, T. Maki, S. Murakami, O. Onomura, *J. Am. Chem. Soc.* **2003**, *125*, 2052
- b) A. Gissibl, M. G. Finn, O. Reiser, *Org. Lett.* **2005**, *7*, 2325.
- c) C. Mazet, S. Roseblade, V. Köhler, A. Pfaltz, *Org. Lett.* **2006**, *8*, 1879.
- d) A. Schätz, R. N. Grass, Q. Kainz, W. J. Stark, O. Reiser, *Chem. Mater.* **2010**, *22*, 305.

Kinetic resolution of *rac*-hydrobenzoin

Equations used to calculate the selectivity factor:

- $(ee \text{ of starting material}) / (ee \text{ of product}) = (\text{conversion}) / (1 - \text{conversion})$
- $s = (\ln[1 - \text{conversion}(1 + ee \text{ of product})]) / (\ln[1 - \text{conversion}(1 - ee \text{ of product})])$



| | RUN | 1 | 2 | 3 | 4 | 5 | 6 |
|---------------------------|-----------------------|-----------|-----------|-----------|-----------|------------|------------|
| (S)- <i>i</i> Pr-DiBox | conv _(exp) | 49 | 50 | 48 | 50 | 45 | 16 |
| | ee | 92 | 86 | 79 | 85 | 59 | <10 |
| | ee' | 93 | 94 | 90 | 82 | 68 | 17 |
| | conv _(th) | 50 | 48 | 47 | 51 | 46 | 10 |
| | s | 91 | 89 | 46 | 27 | 9.4 | 1.4 |
| (R)-Ph-DiBox | conv _(exp) | 49 | 54 | 51 | 53 | 50 | - |
| | ee | 84 | 66 | 76 | 82 | 77 | - |
| | ee' | 83 | 88 | 88 | 90 | 88 | - |
| | conv _(th) | 50 | 43 | 46 | 48 | 47 | - |
| | s | 28 | 31 | 36 | 48 | 36 | - |
| (S)- <i>i</i> Pr-TriBox | conv _(exp) | 47 | 54 | 50 | 50 | - | - |
| | ee | 85 | 84 | 82 | 80 | - | - |
| | ee' | 94 | 67 | 84 | 93 | - | - |
| | conv _(th) | 47 | 45 | 49 | 46 | - | - |
| | s | 88 | 37 | 29 | 49 | - | - |
| (S)- <i>i</i> Pr-TetraBox | conv _(exp) | 45 | 57 | 50 | 44 | - | - |
| | ee | 72 | 81 | 71 | 80 | - | - |
| | ee' | 94 | 92 | 89 | 88 | - | - |
| | conv _(th) | 43 | 47 | 44 | 48 | - | - |
| | s | 70 | 60 | 36 | 38 | - | - |

conv_(exp) = conversion determined by ¹H NMR in the crude.


conv_(th) = conversion determined from the enantiomeric excess of starting material and the enantiomeric excess of product.

[1] A. Abiko, S. Masamune, *Tetrahedron Lett.* **1992**, 33, 5517.

[2] M. Torres, A. Maise-Fançois, S. Bellemin-Laponnaz, *ChemCatChem* **2013**, 5, 3078.

| | Inj. Number | R. Time | Area | Area % | Sample Descrip. | Peak Name |
|---|-------------|---------|-------------|--------|-----------------|-----------|
| 1 | 1 | 11.31 | 29139932.00 | 87.72 | MT_546 | *3 |
| 2 | 1 | 19.21 | 4083272.25 | 12.28 | MT_546 | *4 |

Benzoylation of meso-hydrobenzoin
 Table 1, Entry 2
 Ligand (R,R) Ph-DiBox




| | Inj. Number | R. Time | Area | Area % | Sample Descrip. | Peak Name |
|---|-------------|---------|-------------|--------|-----------------|-----------|
| 1 | 1 | 11.24 | 1180766.25 | 10.06 | MT_558 | *1 |
| 2 | 1 | 19.00 | 10556045.00 | 89.94 | MT_558 | *2 |

Benzoylation of meso-hydrobenzoin


Table 1, Entry 3

Ligand (S,S) iPr-DiBox



| | Inj Number | R. Time | Area | Area % | Sample Descrip. | Peak Name |
|---|------------|---------|------------|--------|-----------------|-----------|
| 1 | 1 | 11.07 | 2195412.25 | 25.32 | MT_561 | *1 |
| 2 | 1 | 18.70 | 6473653.00 | 74.68 | MT_561 | *2 |

Benzoylation of meso-hydrobenzoin
 Table 2, Entry 1, Run 4
 Ligand (S,S) iPr-DiBox




| | Inj. Number | R. Time | Area | Area % | Sample Descrip. | Peak Name |
|---|-------------|---------|-------------|--------|-----------------|-----------|
| 1 | 1 | 11.24 | 3465864.00 | 20.37 | MT_555 | *2 |
| 2 | 1 | 19.00 | 13546493.00 | 79.63 | MT_555 | *3 |

Benzoylation of meso-hydrobenzoin

Table 2, Entry 4, Run 4

Ligand (S,S) iPr-TetraBox




| | Inj. Number | R. Time | Area | Area % | Sample Descrip. | Peak Name |
|---|-------------|---------|-------------|--------|-----------------|-----------|
| 1 | 1 | 9.60 | 971901.81 | 3.47 | MT_582 | *1 |
| 2 | 1 | 11.08 | 995889.38 | 3.55 | MT_582 | *2 |
| 3 | 1 | 12.55 | 8640794.00 | 30.84 | MT_582 | *3 |
| 4 | 1 | 14.31 | 17411008.00 | 62.14 | MT_582 | *4 |

Kinetic Resolution of rac-hydrobenzoin

Peak 1 and 3: hydrobenzoin

Peak 2 and 4: product

Table 3, ligand (S,S) iPr-DiBox, run 3




| | Inj. Number | R. Time | Area | Area % | Sample Descrip. | Peak Name |
|---|-------------|---------|-------------|--------|-----------------|-------------------|
| 1 | 1 | 9.85 | 23364804.00 | 47.66 | MT_581 | *1 |
| 2 | 1 | 11.12 | 21458248.00 | 43.77 | MT_581 | *5 ^{ref} |
| 3 | 1 | 12.66 | 2152407.25 | 4.39 | MT_581 | *7 |
| 4 | 1 | 14.52 | 2046736.12 | 4.18 | MT_581 | *9 |

Kinetic Resolution of rac-hydrobenzoin

Peak 1 and 3: hydrobenzoin


Peak 2 and 4: product

Table 3, ligand (R,R) Ph-DiBox, run 1




| | Inj. Number | R. Time | Area | Area % | Sample Descrip. | Peak Name |
|---|-------------|---------|-------------|--------|-----------------|-----------|
| 1 | 1 | 20.88 | 14759151.00 | 68.15 | MT_247 | *1 |
| 2 | 1 | 24.45 | 6898212.50 | 31.85 | MT_247 | *2 |

Henry reaction
 Table 4, Entry 4
 Ligand (R,R) Ph-Dibox




| | Inj. Number | R. Time | Area | Area % | Sample Descrip. | Peak Name |
|---|-------------|---------|------------|--------|-----------------|-----------|
| 1 | 1 | 20.93 | 4997235.00 | 82.89 | MT_254 | *1 |
| 2 | 1 | 24.51 | 1031672.56 | 17.11 | MT_254 | *2 |

Henry reaction
 Table 4, Entry 5
 Ligand (R,R) iPrBox




| | Inj. Number | R. Time | Area | Area % | Sample Descrip. | Peak Name |
|---|-------------|---------|-------------|--------|-----------------|-----------|
| 1 | 1 | 19.15 | 3943539.75 | 10.50 | MT_112a | *1 |
| 2 | 1 | 21.27 | 33613981.00 | 89.50 | MT_112a | *2 |

Henry reaction
 Table 6, Run 1
 Ligand (S,S) iPr-TetraBox



| | Inj Number | R. Time | Area | Area % | Sample Descrip | Peak Name |
|---|------------|---------|------------|--------|----------------|-----------|
| 1 | 1 | 21.41 | 261480.28 | 12.92 | MT_210 | *1 |
| 2 | 1 | 25.08 | 1763111.00 | 87.08 | MT_210 | *2 |

Henry reaction
Table 6, Run 3
Ligand (S,S) iPr-TetraBox



| | Inj. Number | R. Time | Area | Area % | Sample Descrip. | Peak Name |
|---|-------------|---------|------------|--------|-----------------|-----------|
| 1 | 1 | 21.77 | 865356.31 | 16.67 | MT_217 | *1 |
| 2 | 1 | 25.50 | 4328085.00 | 83.33 | MT_217 | *2 |

Henry reaction
Table 6, Run 5

